

BELIZE

UPDATE: 9 MARCH 2010





Population	Goal Population	Doses acquired	Source*	Laborat.	Adjuvant (yes/no)
4,648	4,648				
7,100	7,100				
24,478	24,478				
277,397					
313,623	36,226	8,000	1	Sanofi	No
	4,648 7,100 24,478 277,397	Population Population 4,648 4,648 7,100 7,100 24,478 24,478 277,397 277,397	Population Population acquired 4,648 4,648	Population Population acquired Source* 4,648 4,648 (7,100) (Population Population acquired Source* Laborat. 4,648 4,648 (1,10) (

* Revolving Fund (1), WHO donation (2), Direct Purchase (3), Direct Country Donation (4).

Pandemic Vaccination Follow Up

Target Risk Groups for Vaccination	Vacc. arrival date	Date of campaign	Doses applied (n) ¹	Vaccine cover. (%) ²	End date of vacc.	Final vacc. coverage
Health personnel and essential workers			2,313	49.8		
Pregnant women						
Chronic disease population (>6 months)						
Other						
Total	2-Feb	14-Feb	2,313	1		

1 Number of doses applied until last week (n).

2 Vaccine coverage achieved until last week (%).

Pandemic Vaccination – ESAVI Surveillance Follow Up

Target Risk Groups for Vaccination	Severe	ESAVI under investig.	ESAVI classification				Rate per
	ESAVI notified		Vaccine related	Program error	Non related	Inconclusi ve	million doses
Health personnel and essential workers	1	0			1		
Pregnant women							
Chronic disease population (>6 months)							
Other							
Total	1	0			1		